214 related articles for article (PubMed ID: 36779841)
1. Single-Cell Discovery and Multiomic Characterization of Therapeutic Targets in Multiple Myeloma.
Yao L; Wang JT; Jayasinghe RG; O'Neal J; Tsai CF; Rettig MP; Song Y; Liu R; Zhao Y; Ibrahim OM; Fiala MA; Fortier JM; Chen S; Gehrs L; Rodrigues FM; Wendl MC; Kohnen D; Shinkle A; Cao S; Foltz SM; Zhou DC; Storrs E; Wyczalkowski MA; Mani S; Goldsmith SR; Zhu Y; Hamilton M; Liu T; Chen F; Vij R; Ding L; DiPersio JF
Cancer Res; 2023 Apr; 83(8):1214-1233. PubMed ID: 36779841
[TBL] [Abstract][Full Text] [Related]
2. Resolving therapy resistance mechanisms in multiple myeloma by multiomics subclone analysis.
Poos AM; Prokoph N; Przybilla MJ; Mallm JP; Steiger S; Seufert I; John L; Tirier SM; Bauer K; Baumann A; Rohleder J; Munawar U; Rasche L; Kortüm KM; Giesen N; Reichert P; Huhn S; Müller-Tidow C; Goldschmidt H; Stegle O; Raab MS; Rippe K; Weinhold N
Blood; 2023 Nov; 142(19):1633-1646. PubMed ID: 37390336
[TBL] [Abstract][Full Text] [Related]
3. The future of myeloma precision medicine: integrating the compendium of known drug resistance mechanisms with emerging tumor profiling technologies.
Harding T; Baughn L; Kumar S; Van Ness B
Leukemia; 2019 Apr; 33(4):863-883. PubMed ID: 30683909
[TBL] [Abstract][Full Text] [Related]
4. A target discovery pipeline identified ILT3 as a target for immunotherapy of multiple myeloma.
Di Meo F; Iyer A; Akama K; Cheng R; Yu C; Cesarano A; Kurihara N; Tenshin H; Aljoufi A; Marino S; Soni RK; Roda J; Sissons J; Vu LP; Guzman M; Huang K; Laskowski T; Broxmeyer HE; Roodman DG; Perna F
Cell Rep Med; 2023 Jul; 4(7):101110. PubMed ID: 37467717
[TBL] [Abstract][Full Text] [Related]
5. Identification of molecular vulnerabilities in human multiple myeloma cells by RNA interference lethality screening of the druggable genome.
Tiedemann RE; Zhu YX; Schmidt J; Shi CX; Sereduk C; Yin H; Mousses S; Stewart AK
Cancer Res; 2012 Feb; 72(3):757-68. PubMed ID: 22147262
[TBL] [Abstract][Full Text] [Related]
6. Human Plasma Extracellular Vesicle Isolation and Proteomic Characterization for the Optimization of Liquid Biopsy in Multiple Myeloma.
Reale A; Khong T; Xu R; Chen M; Mithraprabhu S; Bingham N; Spencer A; Greening DW
Methods Mol Biol; 2021; 2261():151-191. PubMed ID: 33420989
[TBL] [Abstract][Full Text] [Related]
7. Unbiased cell surface proteomics identifies SEMA4A as an effective immunotherapy target for myeloma.
Anderson GSF; Ballester-Beltran J; Giotopoulos G; Guerrero JA; Surget S; Williamson JC; So T; Bloxham D; Aubareda A; Asby R; Walker I; Jenkinson L; Soilleux EJ; Roy JP; Teodósio A; Ficken C; Officer-Jones L; Nasser S; Skerget S; Keats JJ; Greaves P; Tai YT; Anderson KC; MacFarlane M; Thaventhiran JE; Huntly BJP; Lehner PJ; Chapman MA
Blood; 2022 Apr; 139(16):2471-2482. PubMed ID: 35134130
[TBL] [Abstract][Full Text] [Related]
8. Development of gene expression-based score to predict sensitivity of multiple myeloma cells to DNA methylation inhibitors.
Moreaux J; Rème T; Leonard W; Veyrune JL; Requirand G; Goldschmidt H; Hose D; Klein B
Mol Cancer Ther; 2012 Dec; 11(12):2685-92. PubMed ID: 23087257
[TBL] [Abstract][Full Text] [Related]
9. EphA3 targeting reduces in vitro adhesion and invasion and in vivo growth and angiogenesis of multiple myeloma cells.
La Rocca F; Airoldi I; Di Carlo E; Marotta P; Falco G; Simeon V; Laurenzana I; Trino S; De Luca L; Todoerti K; Villani O; Lackmann M; D'Auria F; Frassoni F; Neri A; Del Vecchio L; Musto P; Cilloni D; Caivano A
Cell Oncol (Dordr); 2017 Oct; 40(5):483-496. PubMed ID: 28721629
[TBL] [Abstract][Full Text] [Related]
10. National Cancer Institute Think-Tank Meeting Report on Proteomic Cartography and Biomarkers at the Single-Cell Level: Interrogation of Premalignant Lesions.
Kagan J; Moritz RL; Mazurchuk R; Lee JH; Kharchenko PV; Rozenblatt-Rosen O; Ruppin E; Edfors F; Ginty F; Goltsev Y; Wells JA; LaCava J; Riesterer JL; Germain RN; Shi T; Chee MS; Budnik BA; Yates JR; Chait BT; Moffitt JR; Smith RD; Srivastava S
J Proteome Res; 2020 May; 19(5):1900-1912. PubMed ID: 32163288
[TBL] [Abstract][Full Text] [Related]
11. Multiomics Characterization of Low-Grade Serous Ovarian Carcinoma Identifies Potential Biomarkers of MEK Inhibitor Sensitivity and Therapeutic Vulnerability.
Shrestha R; Llaurado Fernandez M; Dawson A; Hoenisch J; Volik S; Lin YY; Anderson S; Kim H; Haegert AM; Colborne S; Wong NKY; McConeghy B; Bell RH; Brahmbhatt S; Lee CH; DiMattia GE; Le Bihan S; Morin GB; Collins CC; Carey MS
Cancer Res; 2021 Apr; 81(7):1681-1694. PubMed ID: 33441310
[TBL] [Abstract][Full Text] [Related]
12. Survival marker genes of colorectal cancer derived from consistent transcriptomic profiling.
Martinez-Romero J; Bueno-Fortes S; Martín-Merino M; Ramirez de Molina A; De Las Rivas J
BMC Genomics; 2018 Dec; 19(Suppl 8):857. PubMed ID: 30537927
[TBL] [Abstract][Full Text] [Related]
13. secDrug: a pipeline to discover novel drug combinations to kill drug-resistant multiple myeloma cells using a greedy set cover algorithm and single-cell multi-omics.
Kumar H; Mazumder S; Chakravarti S; Sharma N; Mukherjee UK; Kumar S; Baughn LB; Van Ness BG; Mitra AK
Blood Cancer J; 2022 Mar; 12(3):39. PubMed ID: 35264575
[TBL] [Abstract][Full Text] [Related]
14. Ribonucleotide Reductase Catalytic Subunit M1 (RRM1) as a Novel Therapeutic Target in Multiple Myeloma.
Sagawa M; Ohguchi H; Harada T; Samur MK; Tai YT; Munshi NC; Kizaki M; Hideshima T; Anderson KC
Clin Cancer Res; 2017 Sep; 23(17):5225-5237. PubMed ID: 28442502
[No Abstract] [Full Text] [Related]
15. Multi-omic analysis of the tumor microenvironment shows clinical correlations in Ph1 study of atezolizumab +/- SoC in MM.
Wong S; Hamidi H; Costa LJ; Bekri S; Neparidze N; Vij R; Nielsen TG; Raval A; Sareen R; Wassner-Fritsch E; Cho HJ
Front Immunol; 2023; 14():1085893. PubMed ID: 37559718
[TBL] [Abstract][Full Text] [Related]
16. Single-cell transcriptome profiling reveals the key role of ZNF683 in natural killer cell exhaustion in multiple myeloma.
Li X; Chen M; Wan Y; Zhong L; Han X; Chen X; Xiao F; Liu J; Zhang Y; Zhu D; Xiang J; Liu J; Huang H; Hou J
Clin Transl Med; 2022 Oct; 12(10):e1065. PubMed ID: 36245253
[TBL] [Abstract][Full Text] [Related]
17. Integrative Analysis of Bulk RNA-Seq and Single-Cell RNA-Seq Unveils Novel Prognostic Biomarkers in Multiple Myeloma.
Zhao J; Wang X; Zhu H; Wei S; Zhang H; Ma L; He P
Biomolecules; 2022 Dec; 12(12):. PubMed ID: 36551283
[TBL] [Abstract][Full Text] [Related]
18. Transcriptomic profile induced in bone marrow mesenchymal stromal cells after interaction with multiple myeloma cells: implications in myeloma progression and myeloma bone disease.
Garcia-Gomez A; De Las Rivas J; Ocio EM; Díaz-Rodríguez E; Montero JC; Martín M; Blanco JF; Sanchez-Guijo FM; Pandiella A; San Miguel JF; Garayoa M
Oncotarget; 2014 Sep; 5(18):8284-305. PubMed ID: 25268740
[TBL] [Abstract][Full Text] [Related]
19. Tracking myeloma tumor DNA in peripheral blood.
Waldschmidt JM; Vijaykumar T; Knoechel B; Lohr JG
Best Pract Res Clin Haematol; 2020 Mar; 33(1):101146. PubMed ID: 32139012
[TBL] [Abstract][Full Text] [Related]
20. Enrichment-Free Single-Cell Detection and Morphogenomic Profiling of Myeloma Patient Samples to Delineate Circulating Rare Plasma Cell Clones.
Ndacayisaba LJ; Rappard KE; Shishido SN; Ruiz Velasco C; Matsumoto N; Navarez R; Tang G; Lin P; Setayesh SM; Naghdloo A; Hsu CJ; Maney C; Symer D; Bethel K; Kelly K; Merchant A; Orlowski R; Hicks J; Mason J; Manasanch EE; Kuhn P
Curr Oncol; 2022 Apr; 29(5):2954-2972. PubMed ID: 35621632
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
